Registration Dossier

Diss Factsheets

Administrative data

Description of key information

In a repeat-dose inhalation administration study (Mitsubishi, 2001), whole body exposure of trimethylsilane to rats for 28 consecutive days did not result in any findings attributable to treatment. The No-Observed-Adverse-Effect-Concentration (NOAEC) was therefore considered to be 4730 mg/m3 (4.73 mg/L), the highest concentration tested.

Key value for chemical safety assessment

Repeated dose toxicity: via oral route - systemic effects

Endpoint conclusion
Endpoint conclusion:
no study available

Repeated dose toxicity: inhalation - systemic effects

Endpoint conclusion
Endpoint conclusion:
no adverse effect observed
Dose descriptor:
NOAEC
4 730 mg/m³
Study duration:
subacute
Species:
rat

Repeated dose toxicity: inhalation - local effects

Endpoint conclusion
Endpoint conclusion:
no adverse effect observed
Dose descriptor:
NOAEC
4 730 mg/m³
Study duration:
subacute
Species:
rat

Repeated dose toxicity: dermal - systemic effects

Endpoint conclusion
Endpoint conclusion:
no study available

Repeated dose toxicity: dermal - local effects

Endpoint conclusion
Endpoint conclusion:
no study available

Additional information

In a repeat-dose inhalation administration study (Mitsubishi, 2001), whole body exposure of trimethylsilane to rats for 28 consecutive days did not result in any findings attributable to treatment. The No-Observed-Adverse-Effect-Concentration (NOAEC) was therefore considered to be 4730 mg/m3 (4.73 mg/L), the highest concentration tested.


Justification for classification or non-classification

Based on the available data, trimethylsilane does not require classification for specific target organ toxicity following repeated exposure according to Regulation (EC) No 1272/2008.

Categories Display